Sarepta Therapeutics,, Inc. Common Stock
SRPTSarepta Therapeutics, Inc. is a biotechnology company specializing in the development of precision genetic medicines for rare neuromuscular and central nervous system diseases. Known for its pioneering work in RNA-based therapies, Sarepta focuses on delivering targeted treatments for Duchenne muscular dystrophy and other genetic disorders, aiming to improve patient outcomes through innovative RNA modulation technologies.
Company News
The article argues that Recursion Pharmaceuticals and Sarepta Therapeutics, despite significant stock declines, remain unattractive investments. Recursion has no approved products and faces competition in AI-driven drug discovery. Sarepta struggles with safety concerns around its lead therapy Elevidys and faces an uncertain path to regaining mark...
With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a specul...
The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. ...
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100 officially entered correction territory, down over 10% from January highs. The decline was driven by geopolitical tensions with Iran rejecting ceasefire options, surging crude oil prices, deteriorating consumer sentiment, and rising inflation expectati...
U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The market is also bracing for the Federal Reserve's interest rate decision on Wednesday, with markets pricing in a 97.2% likelihood of unchanged rates. Key movers include Baker Hughes (up on strong Q4 results), Sarepta Therapeut...
